Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;141(12):2181-92.
doi: 10.1007/s00432-015-1970-x. Epub 2015 Apr 25.

Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making

Affiliations

Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making

Jonathan R Rees et al. J Cancer Res Clin Oncol. 2015 Dec.

Abstract

Purpose: Randomised controlled trials (RCTs) are the most robust study design measuring outcomes of colorectal cancer (CRC) treatments, but to influence clinical practice trial design and reporting of patient-reported outcomes (PROs) must be of high quality. Objectives of this study were as follows: to examine the quality of PRO reporting in RCTs of CRC treatment; to assess the availability of robust data to inform clinical decision-making; and to investigate whether quality of reporting improved over time.

Methods: A systematic review from January 2004-February 2012 identified RCTs of CRC treatment describing PROs. Relevant abstracts were screened and manuscripts obtained. Methodological quality was assessed using International Society for Quality of Life Research-patient-reported outcome reporting standards. Changes in reporting quality over time were established by comparison with previous data, and risk of bias was assessed with the Cochrane risk of bias tool.

Results: Sixty-six RCTs were identified, seven studies (10 %) reported survival benefit favouring the experimental treatment, 35 trials (53 %) identified differences in PROs between treatment groups, and the clinical significance of these differences was discussed in 19 studies (29 %). The most commonly reported treatment type was chemotherapy (n = 45; 68 %). Improvements over time in key methodological issues including the documentation of missing data and the discussion of the clinical significance of PROs were found. Thirteen trials (20 %) had high-quality reporting.

Conclusions: Whilst improvements in PRO quality reporting over time were found, several recent studies still fail to robustly inform clinical practice. Quality of PRO reporting must continue to improve to maximise the clinical impact of PRO findings.

Keywords: Cancer; Colorectal; Health-related quality of life; Patient-reported outcomes; Randomised; Trails.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Schematic breakdown of literature search results of colorectal randomised controlled trials (preferred reporting items for systematic reviews and meta-analysis). PRO patient-reported outcomes
Fig. 2
Fig. 2
Risk bar chart showing proportion of studies with low, unclear or high risk of bias across all RCTs (n = 66) by quality of PRO reporting
Fig. 3
Fig. 3
Descriptive comparison of level of reporting on selected key PRO issues in RCTs of colorectal describe both clinical and patient-reported outcomes between 1980 and 2003 (yellow bars) (Efficace et al. 2003) and 2004 and 2012 (blue bars)

References

    1. Bauhofer A et al (2007) Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: a randomized, controlled trial. Surgery 141:501–510. doi:10.1016/j.surg.2006.09.004 - PubMed
    1. Brundage M et al (2012) Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 22:1161–1175. doi:10.1007/s11136-012-0252-1 - PMC - PubMed
    1. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, Group CP (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309:814–822. doi:10.1001/jama.2013.879 - PubMed
    1. Chan A-W et al (2013) SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. doi:10.1136/bmj.e7586 - PMC - PubMed
    1. Claassens L et al (2011) Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29:2104–2120. doi:10.1200/JCO.2010.32.3683 - PMC - PubMed

Publication types